Both thyroid autoimmunity and dysfunction are common side effects of IFN-α therapy for CHC, being thyroid autoantibodies the main predisposing factor for the development of thyroid dysfunctions. The gene discussed is IFNA1; the disease is autoimmune thyroid disease.